by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.